Latest Press Releases
Feb 27, 2019 • 4:10pm EST
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for the year ended December 31, 2018. ...